PUBLISHER: Grand View Research | PRODUCT CODE: 1405887
PUBLISHER: Grand View Research | PRODUCT CODE: 1405887
The global blood culture test market size is expected to reach USD 13.23 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 12.3% from 2024 to 2030. Owing to the increasing incidence of bloodstream infections as well as infectious diseases. Rising demand for advanced diagnostic techniques for the diagnosis of infectious diseases, such as sepsis, is also projected to drive growth. Recently, a substantial number of market players are focusing on the development of advanced tests with an aim to improve the efficiency of overall diagnostic procedures. Thus, many manufacturing companies are focusing on the development of advanced diagnostic instruments and consumables.
For instance, in May 2022, Cepheid confirmed that its Xpert Xpress CoV-2plus, a quick molecular diagnostic test for the identification of the infectious virus that causes COVID-19, has obtained the CE mark. Xpert Xpress CoV-2plus unites Xpert Xpress CoV-2/Flu/RSV plus as well as other PCRplus respiratory assessments in Cepheid's diverse range of rapid, reliable, and implementable respiratory results. Such developments are likely to have a positive impact on the growth of the market during the forecast period. The introduction of various government initiatives pertaining to the prevention and control of infections is likely to propel the demand for blood culture tests.
Moreover, the authorities are also focusing on the implementation of strict guidelines to maintain the quality of diagnostics. For instance, in May 2022, CLSI released new National Blood Culture guidelines to prevent and reduce blood culture contaminations. Such regulations are also projected to accelerate the demand by 2030. A massive rise in the number of patients with COVID-19 infection throughout the world resulted in a significant increase in blood culture utilization, which greatly impacted the demand for automated instruments. For instance, in February 2022, Becton, Dickinson, and Company collaborated with ReturnSafe, an all-in-one software application for COVID-19 employee health, well-being, and adherence, to incorporate the BD Verito At-Home COVID-19 Test kits.
This consolidated solution, which uses the ReturnSafe and BD Veritor at-home COVID-19 Test, enables convenient and cost-effective administration of an enterprise's overall population. Key players are focusing on collaborations for the introduction of novel technologies. For instance, in September 2022, OpGen announced a strategic collaboration with FIND for rapid diagnosis of antimicrobial resistance (AMR) with the help of blood culture. Such developments are estimated to offer a favorable environment for market growth.